New combo aims to boost radiation's punch against hard-to-treat prostate cancer

NCT ID NCT05113537

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 22 times

Summary

This study tests whether giving a drug called abemaciclib before a targeted radiation therapy (177Lu-PSMA-617) can help treat metastatic castration-resistant prostate cancer that has stopped responding to other treatments. Abemaciclib may increase the number of targets (PSMA) on cancer cells, making the radiation more effective. About 30 adults with this advanced prostate cancer will take part to find the best dose and see how well the combination works.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STAGE IVB PROSTATE CANCER AJCC V8 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of California, San Francisco

    RECRUITING

    San Francisco, California, 94143, United States

    Contact Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.